Privi Speciality Chemicals Limited reported a robust performance for FY26, achieving a 21.73% growth in annual income to INR 2,582.92 crore. The company saw a significant 75.16% increase in Profit After Tax, reaching INR 327.54 crore. Management highlighted a consistent 25% EBITDA margin, steady demand for aroma chemicals, and a clear expansion roadmap, including the integration of new value-added products and a significant capex program aimed at achieving INR 5,000 crore revenue in the next 3-4 years.
FY26 Financial Highlights
Privi Speciality Chemicals delivered a strong set of results for the fiscal year ended March 31, 2026. The company reported annual revenue of INR 2,582.92 crore, a growth of 21.73% compared to the previous year. Profit After Tax (PAT) witnessed an impressive surge of 75.16%, standing at INR 327.54 crore. EBITDA margins for the year were sustained at a healthy 25.76%, driven by improved product mix, operational efficiencies, and disciplined cost management.
Quarterly Performance
During Q4 FY26 (January-March 2026), the company generated a total income of INR 725.70 crore, marking a 15.29% year-on-year increase. EBITDA for the quarter stood at INR 184.41 crore, with a robust margin of 25.41%. Notably, the joint venture with Givaudan (PRIGIV) turned profitable for the first time in the fourth quarter.
Strategic Growth and Capex Updates
The company remains focused on capacity expansion and vertical integration. The first phase of the ongoing capex expansion is set to be completed by June 30, 2026, increasing total capacity to 54,000 metric tons per annum. Furthermore, the company is advancing its multi-speciality aroma chemicals project and has begun basic engineering for a biomass conversion demonstration plant, requiring an estimated investment of INR 70-75 crore.
Future Outlook
Management expressed confidence in the long-term growth trajectory, reaffirming the vision of reaching INR 5,000 crore in revenue and INR 1,000 crore-plus in EBITDA over the next 3 to 4 years. The strategy includes launching new molecules like ethyl maltol, maltol, and cyclopentanone, while maintaining a strong balance sheet with a net debt-to-equity ratio of 0.62x. The Board has recommended a dividend of INR 10 per share for FY26, reflecting strong cash flow generation and confidence in future business prospects.
Source: BSE
